PTSM: Pharmaceutical Technology Sourcing and Management
Spectrum Pharmacy Products opens pharmacy institute for training in pharmaceutical compounding.
Spectrum Pharmacy Products, a manufacturer and distributor of pharmaceutical compounding chemicals, equipment, and supplies, has opened the Spectrum Pharmacy Institute, a 42,000 sq-ft manufacturing, distribution, and compounding training center in New Brunswick, NJ. The $11 million facility will offer continuing education in compounding to pharmacists and technicians.
The facility, which houses laboratories, offices, and warehouse storage, has 15,000 square feet dedicated to the Spectrum Pharmacy Institute; continuing education classrooms and advanced laboratories are used for hands-on, best practices compounding training.
Courses are taught by national experts and are jointly accredited with the Ernest Mario School of Pharmacy at Rutgers University. The accredited courses provide continuing education units that are required by states that license pharmacists and pharmacy technicians. Courses range from basic compounding techniques to sterile compounding, USP 800 compliance, hormone replacement therapy, pain management, and veterinary compounding.
At a facility opening, Spectrum hosted New Brunswick Mayor Jim Cahill; Rutgers University Pharmacy School dignitaries; international laboratory and pharmacy suppliers; and local and regional pharmacy customers. The facility is expected to provide 50 new jobs.
“We are excited to introduce this state-of-the-art facility to the local community and to pharmacists throughout the US. Our ribbon-cutting ceremony marks the launch of a new business phase for both Spectrum Pharmacy Products and our parent company, Spectrum Chemical,” said Spectrum Pharmacy Products Division President, Dr. Craig A. Recatto in a statement.
Source: Spectrum Pharmacy Products Division
Cosette Pharmaceuticals Adds to Dermatology and Women’s Health Portfolio with Mayne Pharma Purchase
Published: February 26th 2025 | Updated: February 26th 2025While the boards of directors of both companies have approved the transaction, it is not expected to close until the second quarter of 2025, as Mayne Pharma’s shareholders must still vote in favor of the acquisition.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
FDA Approves First Treatment for Rare Lipid Storage Disease Cerebrotendinous Xanthomatosis
February 24th 2025Cerebrotendinous xanthomatosis, or CTX, is a metabolic disorder caused by a gene mutation that results in a deficiency of an important enzyme in the ability of the human body to break down fats.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.